{"brief_title": "Effectiveness of KOS-862 in the Treatment of Lung Cancer", "brief_summary": "The purpose of this study is to determine whether a potential drug known as KOS-862 or \"Epothilone D\" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.", "detailed_description": "To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.", "condition": ["Lung Cancer"], "intervention_type": ["Drug"], "intervention_name": ["KOS-862"], "criteria": "Inclusion Criteria: - At least 18 years of age - Measurable disease - One previous treatment of a platinum based drug such as cisplatin or carboplatin - At least 3 weeks since last surgery/radiation/chemotherapy Exclusion Criteria: - Brain metastases - Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Lung Neoplasms"], "id": "NCT00080509"}